孙进 - 沈阳药科大学

个人简介

孙进，男，博士，教授。1996年毕业于安徽中医学院，获药学学士学位，1998年获沈阳药科大学药剂学硕士学位，2002年获沈阳药科大学药剂学博士学位，博士期间到日本北海道药科大学留学一年。2002年任沈阳药科大学讲师，2004年被聘为沈阳药科大学副教授，2011年被聘为沈阳药科大学教授。作为课题负责人主持了国家和省级科研课题16项，已完成11项，其中包括5项国家自然科学基金。目前已在Nano Lett, TrendsPharmacol Sci, Small, J Control Release, Nanoscale, Biomaterials, Mol Pharm等期刊发表论文160余篇。

研究领域

生物药剂学和纳米药物的研究载体前药和自组装前药纳米粒的研究制剂新技术和新剂型

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Luo C, SunJ*, Liu D, Sun B, Miao L, Musetti S, Li J, Han X, Du Y, Li L, Huang L, HeZ*.Self-Assembled Redox Dual-Responsive Prodrug-Nanosystem Formed by SingleThioether-Bridged Paclitaxel-Fatty Acid Conjugate for Cancer Chemotherapy, NanoLetter , DOI: 10.1021/acs.nanolett.6b01632. (IF=13.78) Luo C, SunJ*, Sun B, He Z*.Prodrug-based nanoparticulate drug delivery strategies forcancer therapy, Trends Pharmacol Sci, DOI: 10.1016/j.tips.2014.09.008.(IF=11.84) Wang G, ChenH, Zhao D, Ding D, Sun M, Kou L, Luo C, Zhang D, Yi X, Dong J, Wang J, Liu X,He Z, Sun J*,Combination of l-Carnitine with Lipophilic Linkage-DonatingGemcitabine Derivatives as Intestinal Novel Organic Cation Transporter2-Targeting Oral Prodrugs, J Med Chem ,DOI:10.1021/acs.jmedchem.7b00049.(IF=5.59) Han X, SunJ*, Wang Y, He Z*.Recent Advances in Platinum (IV) Complex-Based DeliverySystems to Improve Platinum (II) Anticancer Therapy. (Cover Story), Med Res Rev, DOI: 10.1002/med.21360. (IF=9.14) Luo C, SunJ*, Sun BJ, Liu D, Miao L, Goodwin TJ, Huang L, He Z.Facile fabrication oftumor redox-sensitive nanoassemblies of small-molecule oleate prodrug as potentchemotherapeutic nanomedicine, Small, DOI: 10.1002/smll.201601597 (IF=8.32) Wang J, SunJ*, Chen Q, Gao Y, Li L, Li H, Wang Y, Sun Y, Zhu M, Jing Y, Wang S, HeZ*.Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000succinate for doxorubicin delivery with reversal of multidrug resistance, Biomaterials,DOI: 10.1016/j.biomaterials.2012.06.019. (IF=8.39) Zhang P, LingG, Sun J*, Zhang T, Yuan Y, Sun Y, Wang Z, He Z*.Multifunctional nanoassembliesfor vincristine sulfate delivery to overcome mutildrug resistance by escapingP-glycoprotien mediated efflux, Biomaterials, DOI:10.1016/j.biomaterials.2011.04.022. (IF=8.39) Sun J*, LuoC, Wang Y, He Z*.The Holistic 3MModality of Drug Delivery Nanosystems for Cancer Therapy, Nanoscale, DOI:10.1039/c2nr32867d. (IF=7.76) Han X, Li Z,Sun J*, Luo C, Li L, Liu Y, Du Y, Qiu S, Ai X, Wu C, Lian H, He Z*.StealthCD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicindelivery: Probing the effect of uncovalent pegylation degree on cellular uptakeand blood long circulation, J Control Release, DOI: 10.1016/j.jconrel.2014.10.024.(IF=7.44) Luo C, SunJ*, Du Y, He Z*.Emerging Integrated Nanohybrid Drug Delivery Systems toFacilitate the Intravenous-to-OralSwitch in Cancer Chemotherapy, J Control Release, DOI:10.1016/j.jconrel.2013.12.030. (IF=7.44)